ARDX
Ardelyx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.78
+1.89%Year over year
Reported trailing growth
- Revenue
- +16.8%
- EBITDA
- +18.5%
- EBIT
- +12.2%
- EPS
- +3.3%
- Free cash flow
- +67.5%
- Operating cash flow
- +67.6%
Forward estimates
Based on analyst estimates
- Revenue
- +17.0%
- EBITDA
- +267.1%
- EPS
- +102.5%
Three-year CAGR
- Revenue
- +98.4%
- EBITDA
- -74.6%
- EBIT
- -46.6%
- Net income
- -57.4%
- EPS
- -52.9%
- Free cash flow
- +4.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026